Brokerages Set iTeos Therapeutics, Inc. (NASDAQ:ITOS) Target Price at $15.86

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) has been assigned an average rating of "Hold" from the seven research firms that are covering the company, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $15.86.

A number of research analysts have recently issued reports on the stock. Wells Fargo & Company reiterated an "equal weight" rating and issued a $12.00 target price (down previously from $13.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 28th. JPMorgan Chase & Co. downgraded iTeos Therapeutics from an "overweight" rating to a "neutral" rating and cut their price objective for the company from $15.00 to $8.00 in a research report on Tuesday, May 13th. Wedbush lowered iTeos Therapeutics from an "outperform" rating to a "neutral" rating and boosted their price objective for the stock from $10.00 to $12.00 in a research note on Wednesday, May 28th. Raymond James Financial set a $12.00 target price on iTeos Therapeutics in a report on Wednesday, May 14th. Finally, Leerink Partnrs cut iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, May 14th.

Insider Transactions at iTeos Therapeutics

In related news, Director David Hallal sold 38,228 shares of the firm's stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $10.24, for a total value of $391,454.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michel Detheux sold 43,883 shares of iTeos Therapeutics stock in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $10.10, for a total value of $443,218.30. Following the completion of the sale, the chief executive officer owned 135,903 shares of the company's stock, valued at approximately $1,372,620.30. The trade was a 24.41% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,939,307 shares of company stock worth $16,202,116 in the last quarter. 12.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BVF Inc. IL bought a new stake in shares of iTeos Therapeutics during the fourth quarter worth approximately $17,856,000. JPMorgan Chase & Co. grew its holdings in iTeos Therapeutics by 342.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company's stock worth $15,888,000 after acquiring an additional 1,601,477 shares during the period. RA Capital Management L.P. grew its holdings in iTeos Therapeutics by 74.4% during the 1st quarter. RA Capital Management L.P. now owns 3,649,057 shares of the company's stock worth $21,785,000 after acquiring an additional 1,556,798 shares during the period. Boxer Capital Management LLC bought a new position in shares of iTeos Therapeutics in the 4th quarter worth $7,272,000. Finally, 683 Capital Management LLC lifted its stake in iTeos Therapeutics by 90.6% in the first quarter. 683 Capital Management LLC now owns 1,750,000 shares of the company's stock valued at $10,448,000 after buying an additional 831,883 shares during the period. Institutional investors own 97.16% of the company's stock.

iTeos Therapeutics Trading Up 0.1%

ITOS stock traded up $0.01 during trading on Thursday, hitting $10.17. The company had a trading volume of 386,108 shares, compared to its average volume of 692,274. The company has a fifty day moving average price of $8.98 and a two-hundred day moving average price of $7.73. iTeos Therapeutics has a fifty-two week low of $4.80 and a fifty-two week high of $18.13. The company has a market cap of $389.21 million, a P/E ratio of -3.35 and a beta of 1.49.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its quarterly earnings data on Monday, April 28th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.94) by $0.14. On average, analysts expect that iTeos Therapeutics will post -3.49 earnings per share for the current year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.